KURA ONCOLOGY INC (KURA) Stock Price, Forecast & Analysis
USA - NASDAQ:KURA - US50127T1097 - Common Stock
KURA Key Statistics, Chart & Performance
The current stock price of KURA is 10.71 USD. In the past month the price increased by 3.93%. In the past year, price decreased by -35.18%.
KURA Latest News, Press Relases and Analysis
KURA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.71 | 395.87B | ||
| AMGN | AMGEN INC | 15.38 | 181.04B | ||
| GILD | GILEAD SCIENCES INC | 14.9 | 151.42B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.54 | 109.21B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.96 | 71.39B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 891.46 | 59.60B | ||
| INSM | INSMED INC | N/A | 40.65B | ||
| NTRA | NATERA INC | N/A | 28.38B | ||
| BIIB | BIOGEN INC | 9.44 | 23.17B | ||
| INCY | INCYTE CORP | 16.85 | 21.13B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.5 | 20.88B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 35.5 | 14.72B |
Related stock screener links
About KURA
Company Profile
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 192 full-time employees. The company went IPO on 2015-11-05. The firm is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a FTI, is being evaluated in a Phase I dose-escalation trial as a monotherapy and in combination with targeted therapies.
Company Info
KURA ONCOLOGY INC
12730 High Bluff Drive, Suite 400
San Diego CALIFORNIA 92130 US
CEO: Troy E. Wilson
Employees: 192
Phone: 18585008800
KURA ONCOLOGY INC / KURA FAQ
What does KURA ONCOLOGY INC do?
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 192 full-time employees. The company went IPO on 2015-11-05. The firm is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a FTI, is being evaluated in a Phase I dose-escalation trial as a monotherapy and in combination with targeted therapies.
What is the current price of KURA stock?
The current stock price of KURA is 10.71 USD. The price increased by 3.78% in the last trading session.
What is the dividend status of KURA ONCOLOGY INC?
KURA does not pay a dividend.
How is the ChartMill rating for KURA ONCOLOGY INC?
KURA has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of KURA ONCOLOGY INC (KURA) based on its PE ratio?
KURA ONCOLOGY INC (KURA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.48).
What is the market capitalization of KURA stock?
KURA ONCOLOGY INC (KURA) has a market capitalization of 929.63M USD. This makes KURA a Small Cap stock.
KURA Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to KURA. When comparing the yearly performance of all stocks, KURA turns out to be only a medium performer in the overall market: it outperformed 52.7% of all stocks.
KURA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to KURA. KURA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
KURA Financial Highlights
Over the last trailing twelve months KURA reported a non-GAAP Earnings per Share(EPS) of -2.48. The EPS decreased by -5.08% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.4% | ||
| ROE | -89.42% | ||
| Debt/Equity | 0.02 |
KURA Forecast & Estimates
21 analysts have analysed KURA and the average price target is 27.54 USD. This implies a price increase of 157.14% is expected in the next year compared to the current price of 10.71.
For the next year, analysts expect an EPS growth of -25.5% and a revenue growth 948.03% for KURA